117 related articles for article (PubMed ID: 23743668)
1. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus.
Vafadari R; Bouamar R; Hesselink DA; Kraaijeveld R; van Schaik RH; Weimar W; Baan CC; van Gelder T
Ther Drug Monit; 2013 Aug; 35(4):459-65. PubMed ID: 23743668
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
4. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.
Akbas SH; Bilgen T; Keser I; Tuncer M; Yucetin L; Tosun O; Gultekin M; Luleci G
Transplant Proc; 2006 Jun; 38(5):1290-2. PubMed ID: 16797284
[TBL] [Abstract][Full Text] [Related]
5. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
Singh R; Srivastava A; Kapoor R; Mittal RD
J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
7. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis.
Liu YY; Li C; Cui Z; Fu X; Zhang S; Fan LL; Ma J; Li G
Gene; 2013 Dec; 531(2):476-88. PubMed ID: 24042126
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
Capron A; Mourad M; De Meyer M; De Pauw L; Eddour DC; Latinne D; Elens L; Haufroid V; Wallemacq P
Pharmacogenomics; 2010 May; 11(5):703-14. PubMed ID: 20415563
[TBL] [Abstract][Full Text] [Related]
9. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus.
Yan L; Li Y; Tang JT; An YF; Wang LL; Shi YY
Pharmacogenomics; 2016 Feb; 17(3):249-57. PubMed ID: 26784512
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
11. Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients.
Bonhomme-Faivre L; Picard V; Saliba F; Abbara C; Fodil M; Chaunoy M; Farinotti R
Am J Health Syst Pharm; 2009 Sep; 66(18):1645-51. PubMed ID: 19729569
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes.
Noceti OM; Woillard JB; Boumediene A; Esperón P; Taupin JL; Gerona S; Valverde M; Touriño C; Marquet P
Clin Chem; 2014 Oct; 60(10):1336-45. PubMed ID: 25142246
[TBL] [Abstract][Full Text] [Related]
13. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.
Bandur S; Petrasek J; Hribova P; Novotna E; Brabcova I; Viklicky O
Transplantation; 2008 Nov; 86(9):1206-13. PubMed ID: 19005401
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
15. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.
Llaudó I; Colom H; Giménez-Bonafé P; Torras J; Caldés A; Sarrias M; Cruzado JM; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Ekberg H; Grinyó JM; Lloberas N
Transpl Int; 2013 Feb; 26(2):177-86. PubMed ID: 23216707
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
Li D; Gui R; Li J; Huang Z; Nie X
Transplant Proc; 2006 Nov; 38(9):2850-2. PubMed ID: 17112846
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients.
Li Y; Hu X; Cai B; Chen J; Bai Y; Tang J; Liao Y; Wang L
Transpl Immunol; 2012 Aug; 27(1):12-8. PubMed ID: 22504573
[TBL] [Abstract][Full Text] [Related]
18. Effect of MDR1 polymorphisms on the blood concentrations of tacrolimus in Turkish renal transplant patients.
Ciftci HS; Ayna TK; Caliskan YK; Guney I; Bakkaloglu H; Nane I; Aydin AE; Turkmen A; Gurtekin M
Transplant Proc; 2013 Apr; 45(3):895-900. PubMed ID: 23622581
[TBL] [Abstract][Full Text] [Related]
19. The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients.
Riegersperger M; Plischke M; Steinhauser C; Jallitsch-Halper A; Sengoelge G; Winkelmayer WC; Sunder-Plassmann G; Födinger M
Clin Lab; 2016 Oct; 62(10):1965-1972. PubMed ID: 28164520
[TBL] [Abstract][Full Text] [Related]
20. Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms.
Quaglia M; Terrazzino S; Boldorini R; Stratta P; Genazzani AA
J Clin Pharm Ther; 2013 Aug; 38(4):333-6. PubMed ID: 23574377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
